Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …

Importance Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy,
although the risks and benefits of this intervention among outpatients with COVID-19 have not …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins. …

Endothelial injury and microvascular/macrovascular thrombosis are common
pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal …

… Competing interests:Michael Fralick is a co-investigator and Michelle Sholzberg is a
principal investigator on a clinical trial involving patients with COVID-19 coagulopathy. No other …

Introduction Coronavirus disease (COVID‐19) is associated with a high incidence of thrombosis
and mortality despite standard anticoagulant thromboprophylaxis. There is equipoise …

Novel oral anticoagulants (NOACs)(rivaroxaban, dabigatran, apixaban) have been approved
by international regulatory agencies to treat atrial fibrillation and venous thromboembolism …

Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or prevention
of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding, trauma…

Background Pulmonary endothelial injury and microcirculatory thromboses likely contribute
to hypoxemic respiratory failure, the most common cause of death, in patients with COVID‐19…

Iron deficiency (ID) anemia in pregnancy is associated with poor maternal and childhood
outcomes, yet ferritin testing, the standard test for ID, is not considered part of routine prenatal …